In vitro models of a three-drug regimen (epirubicin, cisplatin and fluorouracil) for the treatment of colorectal cancer

Chemotherapy. 2001 Dec;47(6):430-7. doi: 10.1159/000048554.

Abstract

The activity of epirubicin, cisplatin and 5-fluorouracil (5-FU), as single agents or in combination (ECF), was investigated in three human colon cancer cell lines by two different assays (cell-counting assay and sulforhodamine B assay) in vitro. 5-FU was tested with both short and continuous exposure. Particular interest was focused on the results obtained in the HCT8-FU cell line, a subline with experimentally induced resistance to 5-FU. The positive modulation of both cisplatin and epirubicin cytotoxicity by 5-FU makes the ECF regimen an attractive protocol for combination therapy in colorectal cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cell Count
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Colonic Neoplasms / pathology*
  • Drug Interactions
  • Drug Resistance, Neoplasm
  • Epirubicin / administration & dosage
  • Epirubicin / adverse effects
  • Fluorescent Dyes
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Humans
  • Rhodamines
  • Tumor Cells, Cultured

Substances

  • Fluorescent Dyes
  • Rhodamines
  • lissamine rhodamine B
  • Epirubicin
  • Cisplatin
  • Fluorouracil

Supplementary concepts

  • FPEPIR regimen